Improvements in sequencing technology and multigene panel testing have helped identify a growing number of patients with mutations in moderate penetrance genes,1,2 defined as genes associated with a relative risk (RR) of breast cancer that is 2 to 5 times higher than population risk.1,3 These mutations increase primary breast cancer risk by a magnitude similar to the risk associated with atypical ductal or lobular hyperplasias,3 yet little data are available to define the magnitude of the risk of contralateral breast cancer (CBC) in affected individuals. The breast oncology community is faced with counseling patients regarding the advantages and disadvantages of risk-reducing strategies based on scant data. In this article, we summarize the available information on the risk of primary breast cancer and CBC associated with moderate penetrance genes to facilitate surgical risk-reduction counseling.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Weiss A, Garber JE, King T. Breast Cancer Surgical Risk Reduction for Patients With Inherited Mutations in Moderate Penetrance Genes. JAMA Surg. 2018;153(12):1145–1146. doi:10.1001/jamasurg.2018.2493
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: